Literature DB >> 10083455

SDZ RAD inhibits cold ischemia-induced vascular remodeling.

H J Schuurman1, C Pally, G Weckbecker, W Schuler, C Bruns.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10083455     DOI： 10.1016/s0041-1345(98)01885-5

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  10 in total

Review 1.  Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part II.

Authors:  Caroline Monchaud; Pierre Marquet
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 2.  Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part I.

Authors:  Caroline Monchaud; Pierre Marquet
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 3.  mTOR inhibitors in pediatric kidney transplantation.

Authors:  Lars Pape; Thurid Ahlenstiel
Journal:  Pediatr Nephrol       Date:  2013-06-07       Impact factor: 3.714

Review 4.  Everolimus: a review of its use in renal and cardiac transplantation.

Authors:  Christopher Dunn; Katherine F Croom
Journal:  Drugs       Date:  2006       Impact factor: 9.546

5.  Everolimus.

Authors:  Therese M Chapman; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546

6.  The use of everolimus in renal-transplant patients.

Authors:  Julio Pascual
Journal:  Int J Nephrol Renovasc Dis       Date:  2009-06-02

7.  Ischemia-reperfusion injury accelerates human antibody-mediated transplant vasculopathy.

Authors:  Ryoichi Goto; Fadi Issa; Sebastiaan Heidt; David Taggart; Kathryn J Wood
Journal:  Transplantation       Date:  2013-07-27       Impact factor: 4.939

8.  Renal function in heart transplant patients after switch to combined mammalian target of rapamycin inhibitor and calcineurin inhibitor therapy.

Authors:  Matthias Helmschrott; Rasmus Rivinius; Thomas Bruckner; Hugo A Katus; Andreas O Doesch
Journal:  Drug Des Devel Ther       Date:  2017-06-07       Impact factor: 4.162

9.  The CECARI Study: Everolimus (Certican®) Initiation and Calcineurin Inhibitor Withdrawal in Maintenance Heart Transplant Recipients with Renal Insufficiency: A Multicenter, Randomized Trial.

Authors:  Jan Van Keer; David Derthoo; Olivier Van Caenegem; Michel De Pauw; Eric Nellessen; Nathalie Duerinckx; Walter Droogne; Gábor Vörös; Bart Meyns; Ann Belmans; Stefan Janssens; Johan Van Cleemput; Johan Vanhaecke
Journal:  J Transplant       Date:  2017-02-20

10.  A 3-month, Multicenter, Randomized, Open-label Study to Evaluate the Impact on Wound Healing of the Early (vs Delayed) Introduction of Everolimus in De Novo Kidney Transplant Recipients, With a Follow-up Evaluation at 12 Months After Transplant (NEVERWOUND Study).

Authors:  Tommaso Maria Manzia; Mario Carmellini; Paola Todeschini; Antonio Secchi; Silvio Sandrini; Enrico Minetti; Lucrezia Furian; Gionata Spagnoletti; Francesco Pisani; Gian Benedetto Piredda; Gianni Cappelli; GIuseppe Tisone
Journal:  Transplantation       Date:  2020-02       Impact factor: 5.385
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.